

ANTONSSON et al
Appl. No. 10/776,245
August 13, 2007


RECEIVED
CENTRAL FAX CENTER

AUG 13 2007

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1 (currently amended). A pharmaceutical formulation comprising an effective amount of acetylsalicylic acid and a compound of formula I,



wherein

R^1 represents $-R^3$ or $-A^1C(O)N(R^4)R^5$ in which A^1 represents C_{1-3} alkylene or $-A^1C(O)OR^4$ in which A^1 represents C_{1-5} alkylene;

A^1 represents C_{4-6} alkylene;

R^2 (which replaces one of the hydrogen atoms in the amidino unit of Pab-H) represents OH, $OC(O)R^6$, $C(O)OR^7$ or $C(O)OCH(R^8)OC(O)R^9$;

R^3 represents H, C_{1-10} alkyl, or C_{1-3} alkylphenyl (which latter group is optionally substituted by C_{1-6} alkyl, C_{1-6} alkoxy, nitro or halogen);

R^4 and R^5 independently represent H, C_{1-6} alkyl, phenyl, 2-naphthyl or, when R^1 represents $-A^1C(O)N(R^4)R^5$, together with the nitrogen atom to which they are attached represent pyrrolidinyl or piperidinyl;

R^6 represents C_{1-17} alkyl, phenyl or 2-naphthyl (all of which are optionally substituted by C_{1-6} alkyl or halogen);

R^7 represents 2-naphthyl, phenyl, C_{1-3} alkylphenyl (which latter three groups are optionally substituted by C_{1-6} alkyl, C_{1-6} alkoxy, nitro or halogen), or C_{1-12} alkyl (which latter group is optionally substituted by C_{1-6} alkoxy, C_{1-6} acyloxy or halogen);

R^8 represents H or C_{1-4} alkyl; and

ANTONSSON et al
Appl. No. 10/776,245
August 13, 2007

R^9 represents 2-naphthyl, phenyl, C_{1-6} alkoxy or C_{1-8} alkyl (which latter group is optionally substituted by halogen, C_{1-6} alkoxy or C_{1-6} acyloxy); provided that:

when R^1 represents R^3 , R^3 represents benzyl, methyl, ethyl, *n*-butyl or *n*-hexyl and R^2 represents $C(O)OR^7$, then R^7 does not represent benzyl; and

when R^1 represents $-A^1C(O)N(R^4)R^5$, A^1 represents C_{1-3} alkylene;

or a pharmaceutically-acceptable salt thereof.

2 (canceled).

3 (previously presented). A formulation, as defined in Claim 1, wherein, in the compound of formula I, R^4 represents H or C_{1-6} alkyl when R^1 represents $-A^1C(O)N(R^4)R^5$.

4 (previously presented). A formulation, as defined in Claim 1, wherein, in the compound of formula I, R^5 represents C_{1-6} alkyl or C_{4-6} cycloalkyl when R^1 represents $-A^1C(O)N(R^4)R^5$.

5 (previously presented). A formulation, as defined in Claim 1, wherein, in the compound of formula I, R^4 and R^5 together represent pyrrolidinyl when R^1 represents $-A^1C(O)N(R^4)R^5$.

6 (previously presented). A formulation, as defined in Claim 1, wherein, in the compound of formula I, A^1 represents C_{1-3} alkylene, and R^4 represents H or C_{1-3} alkyl

ANTONSSON et al
Appl. No. 10/776,245
August 13, 2007

and R⁵ represents C₂₋₆ alkyl or C₅₋₆ cycloalkyl, or R⁴ and R⁵ together represent pyrrolidinyl.

7 (previously presented). A formulation, as defined in Claim 1, wherein, in the compound of formula I, A¹ represents C₁₋₅ alkylene when R¹ represents -A¹C(O)OR⁴.

8 (previously presented). A formulation, as defined in Claim 1, wherein, in the compound of formula I, R⁴ represents C₁₋₆ alkyl when R¹ represents -A¹C(O)OR⁴.

9 (previously presented). A formulation, as defined in Claim 7, wherein A¹ represents C₁₋₅ alkylene and R⁴ represents C₁₋₄ alkyl.

10 (previously presented). A formulation, as defined in Claim 1, wherein, in the compound of formula I, R³ represents H, C₁₋₁₀ alkyl (which latter group is optionally linear or, when there are a sufficient number of carbon atoms, is optionally branched and/or be partially cyclic or cyclic), or C₁₋₃ alkylphenyl (which latter groups is optionally substituted, is optionally linear or, when there are a sufficient number of carbon atoms, is optionally branched), when R¹ represents R³.

11 (previously presented). A formulation as claimed in Claim 1, wherein, in the compound of formula I, R¹ represents H, linear C₁₋₁₀ alkyl, branched C₃₋₁₀ alkyl, partially cyclic C₄₋₁₀ alkyl, C₄₋₁₀ cycloalkyl, optionally substituted linear C₁₋₃ alkylphenyl, optionally substituted branched C₃ alkylphenyl.

ANTONSSON et al
Appl. No. 10/776,245
August 13, 2007

12 (previously presented). A formulation as claimed in Claim 11, wherein R^1 represents linear C_{1-6} alkyl, C_{6-10} cycloalkyl, or optionally substituted linear C_{1-3} alkylphenyl.

13 (previously presented). A formulation, as defined in Claim 1, wherein, in the compound of formula I, R^2 represents OH.

14 (previously presented). A formulation, as defined in Claim 1, wherein, in the compound of formula I, R^6 represents optionally substituted phenyl or C_{1-17} alkyl (which latter group is optionally linear or, when there are a sufficient number of carbon atoms, is optionally branched, is optionally cyclic or partially cyclic, and/or is optionally saturated or unsaturated) when R^2 represents $OC(O)R^6$.

15 (previously presented). A formulation as claimed in Claim 14 wherein R^6 represents optionally substituted phenyl, linear C_{1-4} alkyl, branched C_{1-3} alkyl or *cis*-oleyl.

16 (previously presented). A formulation as claimed in Claim 15 wherein R^6 represents linear C_{1-3} alkyl or branched C_3 alkyl.

17 (currently amended). A formulation, as defined in Claim 1, wherein, in the compound of formula I, R^7 represents optionally substituted phenyl, C_{1-12} alkyl (which

ANTONSSON et al
Appl. No. 10/776,245
August 13, 2007

latter group is optionally substituted, is optionally linear or, when there are a sufficient number of carbon atoms, is optionally branched, cyclic or partially cyclic, and/or saturated or unsaturated), or C₁₋₃ alkylphenyl (which latter group is optionally substituted, is optionally linear or, when there are a sufficient number of carbon atoms, is optionally branched) when R² represents C(O)OR⁷.

18 (previously presented). A formulation in Claim 17 wherein R⁷ represents optionally substituted and/or optionally unsaturated linear C₁₋₄ alkyl or optionally substituted and/or optionally unsaturated branched C₃₋₄ alkyl, optionally substituted phenyl, or optionally substituted linear C₁₋₃ alkylphenyl or optionally substituted branched C₃ alkylphenyl.

19 (previously presented). A formulation as claimed in Claim 18 wherein R⁷ represents optionally substituted linear C₁₋₄ alkyl or optionally substituted branched C₃₋₄ alkyl, optionally substituted linear C₁₋₃ alkylphenyl or branched C₃ alkylphenyl.

20 (previously presented). A formulation, as defined in Claim 1, wherein, in the compound of formula I, R⁸ represents H or methyl, when R² represents C(O)OCH(R⁸)OC(O)R⁹.

21 (previously presented). A formulation, as defined in Claim 1, wherein, in the compound of formula I, R⁹ represents phenyl, or C₁₋₈ alkyl (which latter group is optionally substituted, is optionally linear or, when there are a sufficient number of

ANTONSSON et al
Appl. No. 10/776,245
August 13, 2007

carbon atoms, is optionally branched and/or cyclic or partially cyclic) when R^2 represents $C(O)OCH(R^8)OC(O)R^9$.

22 (previously presented). A formulation, as defined in Claim 20 wherein R^8 represents H or methyl and R^9 represents phenyl, C_{5-7} cycloalkyl, linear C_{1-6} alkyl, branched C_{3-6} alkyl or partially cyclic C_{7-8} alkyl.

23 (previously presented). A formulation as claimed in Claim 22 wherein R^8 represents H and R^9 represents C_{5-7} cycloalkyl, linear C_{1-6} alkyl or partially cyclic C_{7-8} alkyl.

24 (previously presented). A formulation as claimed in Claim 1 wherein, in the compound of formula I, when R^1 represents R^3 and R^3 represents optionally substituted C_{1-3} alkylphenyl, the optional substituent C_{1-6} alkyl.

25 (previously presented). A formulation as claimed in Claim 24 wherein the substituent is methyl.

26 (previously presented). A formulation as claimed in Claim 1 wherein, in the compound of formula I, when R^2 represents $C(O)OR^7$ and R^7 represents optionally substituted C_{1-12} alkyl, the optional substituent is selected from halogen and C_{1-6} alkoxy.

ANTONSSON et al
Appl. No. 10/776,245
August 13, 2007



27 (previously presented). A formulation as claimed in Claim 26 wherein the substituent is selected from chloro and methoxy.

28 (previously presented). A formulation as claimed in Claim 1 wherein, in the compound of formula I, when R^2 represents $C(O)OR^7$ and R^7 represents optionally substituted phenyl, the optional substituent is selected from C_{1-6} alkyl, C_{1-6} alkoxy and halogen.

29 (previously presented). A formulation as claimed in Claim 28 wherein the substituent is selected from methyl, methoxy and chloro.

30 (previously presented). A formulation as claimed in Claim 1 wherein, in the compound of formula I, when R^2 represents $C(O)OR^7$ and R^7 represents optionally substituted C_{1-3} alkylphenyl, the optional substituent is nitro.

31 (previously presented). A formulation as claimed in Claim 1 wherein the compound of formula I is



ANTONSSON et al
Appl. No. 10/776,245
August 13, 2007

ChNHC(O)CH₂OOCCH₂-(*R*)Cgl-Aze-Pab-Z;
(*n*Pr)₂NC(O)CH₂OOCCH₂-(*R*)Cgl-Aze-Pab-COOCH₂OCCC(CH₃)₃;
EtOOCCH₂-(*R*)Cgl-Aze-Pab-COOCH₂OCCC(CH₃)₃;
EtOOCCH₂-(*R*)Cgl-Aze-Pab-COOCH(CH₃)OOCCH₃;
MeOOCCH₂-(*R*)Cgl-Aze-Pab-OOCPh;
MeOOCCH₂-(*R*)Cgl-Aze-Pab-OH;
EtOOCCH₂-(*R*)Cgl-Aze-Pab-OH;
BnOOCCH₂-(*R*)Cgl-Aze-Pab-OH;
*n*PrOOCCH₂-(*R*)Cgl-Aze-Pab-Z;
*n*PrOOCCH₂-(*R*)Cgl-Aze-Pab-OH;
*i*PrOOCCH₂-(*R*)Cgl-Aze-Pab-OH;
*t*BuOOCCH₂-(*R*)Cgl-Aze-Pab-OH;
(*n*Pr)₂NCOCH₂OOCCH₂-(*R*)Cgl-Aze-Pab-OH;
ChNHC(O)CH₂OOCCH₂-(*R*)Cgl-Aze-Pab-OH;
EtOOCCH₂-(*R*)Cgl-Aze-Pab-OAc;
HOOCCH₂-(*R*)Cgl-Aze-Pab-OH;
HOOCCH₂-(*R*)Cgl-Aze-Pab-O-*cis*-Oleyl;
Cyclooctyl-OOCCH₂-(*R*)Cgl-Aze-Pab-Z;
*t*BuCH₂OOCCH₂-(*R*)Cgl-Aze-Pab-Z;
(2-Me)BnOOCCH₂-(*R*)Cgl-Aze-Pab-Z;
ChCH₂OOCCH₂-(*R*)Cgl-Aze-Pab-Z;
ChOOCCH₂-(*R*)Cgl-Aze-Pab-Z;
PhC(Me)₂OOCCH₂-(*R*)Cgl-Aze-Pab-Z;

ANTONSSON et al
Appl. No. 10/776,245
August 13, 2007

(Me)₂CHC(Me)₂OOCCH₂-(*R*)Cgl-Aze-Pab-Z;
BnOOCCH₂-(*R*)Cgl-Aze-Pab-COOPh(4-OMe);
ChCH₂OOCCH₂-(*R*)Cgl-Aze-Pab-COOPh(4-OMe);
(2-Me)BnOOCCH₂-(*R*)Cgl-Aze-Pab-COOPh(4-OMe);
EtOOCCH₂-(*R*)Cgl-Aze-Pab-COOPh(4-Me);
BnOOCCH₂-(*R*)Cgl-Aze-Pab-COOPh(4-Me);
BnOOCCH₂-(*R*)Cgl-Aze-Pab-COO-*n*Bu;
*i*PrOOCCH₂-(*R*)Cgl-Aze-Pab-COOCH₂CH=CH₂;
EtOOCCH₂-(*R*)Cgl-Aze-Pab-COO-*i*Bu;
BnOOCCH₂-(*R*)Cgl-Aze-Pab-COO-*n*Pr;
EtOOCCH₂-(*R*)Cgl-Aze-Pab-COOCH₂OOCCh;
EtOOCCH₂-(*R*)Cgl-Aze-Pab-COOCH₂OOCCH₂Ch;
EtOOCCH₂-(*R*)Cgl-Aze-Pab-COOCH(Me)OOCPh;
EtOOCCH₂-(*R*)Cgl-Aze-Pab-COOCH₂OOCPh;
BnOOCCH₂-(*R*)Cgl-Aze-Pab-COOCH(Me)OAc;
EtOOCCH₂-(*R*)Cgl-Aze-Pab-COOCH₂OAc;
*i*BuOOCCH₂-(*R*)Cgl-Aze-Pab-COOCH₂OAc;
MeOOC-C(=CH₂Et)CH₂-OOCCH₂-(*R*)Cgl-Aze-Pab-Z;
Men-OOCCH₂-(*R*)Cgl-Aze-Pab-COOPh(4-OMe); and
EtOOCCH₂-(*R*)Cgl-Aze-Pab-COOCH₂CCl₃.

32 (previously presented). A formulation as claimed in Claim 1 wherein the compound of formula I is

ANTONSSON et al
Appl. No. 10/776,245
August 13, 2007

EtOOCCH₂-(*R*)Cgl-Aze-Pab-COOCH₂CCl₃;
BnOOCCH₂-(*R*)Cgl-Aze-Pab-COOnBu;
*n*PrOOCCH₂-(*R*)Cgl-Aze-Pab-Z;
Cyclooctyl-OOCCH₂-(*R*)Cgl-Aze-Pab-Z;
EtOOCCH₂-(*R*)Cgl-Aze-Pab-COOCH₂OOCch;
MeOOCCH₂-(*R*)Cgl-Aze-Pab-OH;
EtOOCCH₂-(*R*)Cgl-Aze-Pab-OH;
*n*PrOOCCH₂-(*R*)Cgl-Aze-Pab-OH;
*i*PrOOCCH₂-(*R*)Cgl-Aze-Pab-OH
BnOOCCH₂-(*R*)Cgl-Aze-Pab-OH; and
EtOOCCH₂-(*R*)Cgl-Aze-Pab-OAc.

33 (previously presented). A formulation, as defined in Claim 1, with the additional proviso that, in the compound of formula I, R¹ does not represent -A¹C(O)OR⁴.

34 (previously presented). A formulation, as defined in Claim 1, with the additional proviso that, in the compound of formula I, R⁴ and R⁵ do not independently represent H.

35 (previously presented). A formulation, as defined in Claim 1, with the additional proviso that, in the compound of formula I, R⁶ does not represent C₁₋₁₇ alkyl, when R² represents OC(O)R⁶.

ANTONSSON et al
Appl. No. 10/776,245
August 13, 2007

36 (previously presented). A formulation, as defined in Claim 1, wherein, in the compound of formula I, R^1 represents $-A^1C(O)OR^4$.

37 (previously presented). A formulation, as defined in Claim 1, wherein, in the compound of formula I, R^4 and R^5 independently represent H.

38 (previously presented). A formulation, as defined in Claim 1, wherein, in the compound of formula I, R^6 represents C_{1-17} alkyl, when R^2 represents $OC(O)R^6$.

39-46 (cancelled).

47 (withdrawn). A method of treatment of a condition where inhibition of thrombin is required which method comprises administration of a therapeutically effective amount of a formulation as defined in Claim 1 or claim 52, or a pharmaceutically acceptable salt thereof, to a person suffering from, or susceptible to, such a condition.

48 (withdrawn). A method as claimed in Claim 47, wherein the condition is thrombosis.


49 (withdrawn). A method as claimed in claim 47, wherein the condition is hypercoagulability in blood and tissues.

ANTONSSON et al
Appl. No. 10/776,245
August 13, 2007

50-51 (cancelled).

52 (previously presented). A formulation as claimed in claim 1, wherein the compound of formula I is $\text{EtOOCCH}_2\text{-(R)Cgl-Aze-Pab-OH}$.

53 (previously presented). A combination comprising (a) acetylsalicylic acid and (b) a compound of the formula I as defined in claim 1,



54 (previously presented). A combination comprising (a) acetylsalicylic acid and (b) the compound $\text{EtOOCCH}_2\text{-(R)Cgl-Aze-Pab-OH}$ or a pharmaceutically-acceptable salt thereof.

55 (previously presented). A combination comprising (a) acetylsalicylic acid and (b) the compound $\text{EtOOCCH}_2\text{-(R)Cgl-Aze-Pab-OH}$.

56 (previously presented). A combination as claimed in Claim 53 which comprises a kit of parts comprising components (a) and (b).

57 (previously presented). A combination product as claimed in Claim 53, in which components (a) and (b) are suitable for sequential, separate and/or simultaneous use in the treatment of a condition where inhibition of thrombin is required.

ANTONSSON et al
Appl. No. 10/776,245
August 13, 2007

58 (previously presented). A combination product as claimed in Claim 57, wherein component (a) is combined with component (b).

59 (withdrawn). A method of treatment of a condition where inhibition of thrombin is required, which method comprises administration of an effective amount of a combination as claimed in Claim 53.

60 (withdrawn). A method of treatment of a condition where inhibition of thrombin is required, which method comprises administration of an effective amount of a combination as claimed in Claim 54.

61 (withdrawn). A method of treatment of a condition where inhibition of thrombin is required, which method comprises administration of an effective amount of a combination as claimed in Claim 55.

62 (withdrawn). A method of treatment of a condition where inhibition of thrombin is required, which method comprises administration of a therapeutically effective amount of components (a) and (b) of a combination as claimed in Claim 53 separately, sequentially or simultaneously.

63 (withdrawn). A method of treatment of thrombosis or of hypercoagulability in blood and tissues, which comprises administration of an effective amount of a

ANTONSSON et al
Appl. No. 10/776,245
August 13, 2007

combination as claimed in Claim 53.

64 (withdrawn). A method of treatment of thrombosis or of hypercoagulability in blood and tissues, which comprises administration of an effective amount of a combination as claimed in Claim 54.

65 (withdrawn). A method of treatment of thrombosis or of hypercoagulability in blood and tissues, which comprises administration of an effective amount of a combination as claimed in Claim 55.